Your NGS report
decoded.
Your treatment strategy
refined.
A molecular second opinion in oncology. We transform complex genomic sequencing data into clear, actionable clinical recommendations—bridging the gap between laboratory findings and treatment decisions.
Raw genomic data is noise.
Our job is to make it
signal.
Raw NGS Output
Hundreds of variants across DNA, RNA, protein. Annotation thin or absent. Clinical relevance unsorted.
Filter
Strip artifacts, germline noise, low-coverage calls. Retain candidates with somatic confidence.
Prioritize
Rank by oncogenic role, allele frequency, pathway position, and clinical actionability score.
Interpret
Match each driver to FDA labels, guideline rec's, trials, and emerging literature. Tier 1 / 2 / 3.
Decide
Physician-reviewed roadmap: 1L → 2L → 3L+ with anticipated resistance and trial alternatives.
DNA alone misses what changes lives.
Many oncologists order only a DNA-based NGS panel. We integrate DNA · RNA · protein (IHC) · germline — because a single missing layer can hide a Tier IA finding.
Cholangiocarcinoma · 40 yo
A 648-gene DNA panel returned zero actionable variants. On paper, the tumor had no therapeutic targets.
RNA fusion analysis detected an FGFR2-VCL fusion—a Tier IA finding with two FDA-approved therapies (futibatinib, pemigatinib).
DNA panels miss intronic-breakpoint fusions outside probe coverage.
RNA detects the transcript regardless of breakpoint location.
The report you receive today.
The roadmap we deliver instead.
- — Long variant tables — driver and passenger undifferentiated
- — Annotation thin · clinical relevance unscored
- — No therapy sequencing · no resistance plan
- — Trial mentions generic, not HLA-matched
- Prioritized drivers — actionability scored 0–100
- Tier 1/2/3 evidence framework on every recommendation
- Sequenced 1L → 2L → 3L+ with anticipated resistance
- HLA + molecular trial matching · physician-signed
Precision Targeting.
Drivers at the center.
Context
in the periphery.
Treatment as a
journey—
not a list of drugs.
Evidence in strata.
So physicians always know how strong the ground is.
Six steps beyond the standard report.
Standard NGS reports list mutations and mention drug matches. We add six layers your treating oncologist can act on immediately.
Variant Tier Classification
Every variant graded Tier IA → IV per current NCCN, MSK OncoKB, and FDA — and re-graded against your tumor type. A mutation that is Tier IA in lung may be Tier II elsewhere. We make that distinction explicit.
Immunotherapy Suitability Score
A quantitative IO score from five parameters: TMB · MSI · PD-L1 · active driver penalty · ultra-low TMB penalty. Positive = IO candidate. Zero or negative = IO not recommended as monotherapy.
Treatment Sequencing 1L → 2L → 3L+
Cancer treatment is a sequence, not a decision. Preferred 1L with alternatives, 2L matched to expected resistance, 3L+ with experimental and trial options — each annotated with ORR, PFS, OS evidence.
Anticipatory Resistance Strategy
A 4-step plan: (1) what to test at progression, (2) which resistance mutations to expect, (3) which next-gen agents address each, (4) which trials to reserve. For FGFR2 — V564F, N549K · tinengotinib · lirafugratinib.
Clinical Trial Matching
Independent, real-time matching against ClinicalTrials.gov and institutional databases. Molecular + HLA + geography (Türkiye, Balkans, EU prioritized). NCT, phase, city, and exact eligibility per match.
First-Person Physician Commentary
Every report includes a dedicated commentary written in the first person by Prof. İbrahim Yıldız — a clinical letter your treating oncologist can act on directly, in plain language.
From NGS upload to clinical advisory.
A streamlined, secure process for both referring oncologists and patients seeking molecular second opinions.
Upload your NGS
Send your NGS report (Tempus, FoundationOne, Guardant, Caris, or any panel) via our secure portal with basic clinical context.
Multi-platform analysis
DNA · RNA · protein · IHC integrated. Cross-referenced with current NCCN guidelines, FDA approvals, and active clinical trials.
Expert review
Prof. İbrahim Yıldız personally reviews every case — validating tier classifications, treatment recommendations, and trial matches.
Report delivery
Two documents within 48–72 h: the structured IYGAS™ advisory and the physician commentary. Optional video consultation.
Two documents.
One complete picture.
Every consultation produces two complementary reports — a structured English-language molecular advisory and a physician commentary in your preferred language.
IYGAS™ Molecular Advisory
14 SECTIONS- 01 Patient demographics & specimen context
- 02 Executive clinical summary · critical findings
- 03 Genomic & biomarker profile (all platforms)
- 04 VAF & clonality interpretation model
- 05 Auto-tier classification (IA → IV)
- 06 Treatment decision matrix (1L / 2L / 3L+)
- 07 Immunotherapy suitability score
- 08 4-step resistance management strategy
- 09 Pharmacogenomics · dose & toxicity
- 10 Drug interactions vs. planned therapy
- 11 Clinical trial matching framework
- 12 VUS registry with biological context
- 13 Evidence library & literature support
- 14 Physician advisory conclusion + signature
Physician Commentary
MULTILINGUAL- — First-person clinical narrative by Prof. Yıldız
- — "Why this finding matters" — explained, not just listed
- — "Why I recommend this treatment" — with evidence rationale
- — "Why immunotherapy is/isn't appropriate" — IO score explained
- — VUS interpretation with biological mechanism
- — Clinical trial recommendations with eligibility context
- — Age/gender-specific considerations (fertility, germline)
- — Available in TR · EN · BG · RO · BA
Clear packages. No hidden fees.
Two service tiers based on how much support you need beyond the written report. Every case is personally reviewed and signed by Prof. İbrahim Yıldız.
Complete fourteen-section written interpretation. For patients with a clear clinical trajectory seeking a definitive second read.
- 14-section structured IYGAS™ report
- Variant interpretation & therapy matching
- Active clinical trial recommendations
- Patient-readable summary
- 30-day email follow-up support
- 3 business day delivery
Everything in Standard, plus a 30-minute personal video consultation with Prof. Yıldız to walk through findings.
- Everything included in Standard
- 30-min video consultation w/ Prof. Yıldız
- Referring physician dialogue (optional)
- Priority turnaround — 48 hours
- 60-day follow-up support
- Languages: EN · TR · BG · RO · BA
One platform
Three ways in
A clinical co-pilot, not a lab printout.
Workflow-integrated reports. EHR-compatible exports. Outcomes data. Direct line to the reviewing oncologist.
Why your doctor sent your report here.
We translate the genomic findings on your report into the treatment options your doctor will discuss with you—in plain language, with privacy protected.
Expert-led. Technology-powered.
NGS Advisory is a boutique molecular oncology advisory — a small, specialized team combining deep clinical experience, cancer genomics expertise, and advanced technology.
Prof. İbrahim Yıldız, MD
Professor of Medical Oncology at Acıbadem Mehmet Ali Aydınlar University, Istanbul. Member of ASCO and ESMO. Author of 130+ peer-reviewed publications. Personally reviews and signs every advisory.
Assoc. Prof. Taşcı
Associate Professor specializing in cancer genomics, multi-platform NGS interpretation, and clinical trial matching. Leads the platform integration layer (DNA · RNA · protein · germline).
Genomics Consultant
Our genomics consultant is a specialist in cancer molecular biology with expertise in NGS data interpretation, variant annotation, and molecular pathway analysis. Their role is to ensure every genomic finding — from single nucleotide variants to complex structural rearrangements — is accurately characterized, correctly classified, and placed in the appropriate biological context.
Key responsibilities include multi-platform data integration (DNA + RNA + IHC), variant of unknown significance (VUS) biological assessment, clonal architecture interpretation, and quality control of genomic data accuracy. This layer of expertise ensures that the clinical recommendations built on top of the genomic data are based on correctly interpreted molecular findings — including cases where DNA and RNA results appear discordant and require careful biological explanation.
Software Engineer
The architect behind the Ibrahim Yildiz Genomic Advisory System™ (IYGAS) — the proprietary platform that structures, formats, scores, and produces our molecular advisory reports. The system integrates multi-platform NGS data, calculates immunotherapy suitability scores, generates tier classifications, and produces publication-quality formatted reports with color-coded clinical tables.
The IYGAS platform is not a generic template — it dynamically generates each report based on the individual patient’s genomic profile, tumor type, and available platform data. It incorporates real-time web verification of clinical trial statuses, FDA approval databases, and current NCCN guideline versions. The system enforces internal quality controls including VAF cross-referencing, platform-source tracking, and amber-field flagging for missing clinical data that must be completed by the treating physician.
Questions we hear most.
Your NGS report decoded. Your treatment strategy refined.
A molecular second opinion in oncology. We turn complex genomic sequencing into clear, actionable clinical recommendations.
From NGS upload to clinical advisory.
A streamlined, secure process for referring oncologists and patients seeking a molecular second opinion.
Send your report (Tempus, FoundationOne, Guardant, Caris, or any panel) via our secure portal with basic clinical context.
DNA · RNA · protein · IHC integrated, cross-referenced with current NCCN guidelines, FDA approvals, and active trials.
Prof. İbrahim Yıldız personally reviews every case, validating tier classifications, recommendations, and trial matches.
Two documents within 48–72 h: the structured IYGAS™ advisory and the physician commentary. Optional video consult.
Two documents.
One complete picture.
A structured English-language molecular advisory, plus a physician commentary in your preferred language.
- 02Executive clinical summary · critical findings
- 05Auto-tier classification (IA → IV)
- 06Treatment decision matrix (1L / 2L / 3L+)
- 07Immunotherapy suitability score
- 084-step resistance management strategy
- 11Clinical trial matching framework
- +…and 8 further sections, end to end
- ·First-person clinical narrative by Prof. Yıldız
- ·“Why this finding matters,” not just what it is
- ·“Why I recommend this treatment”, with the evidence
- ·IO score & VUS interpretation, in plain language
- ·Available in TR · EN · BG · RO · BA
Six layers beyond the standard report.
Standard NGS reports list mutations and mention drug matches. We add layers your treating oncologist can act on immediately.
Every variant graded Tier IA → IV per NCCN, OncoKB and FDA, then re-graded against your specific tumor type.
A quantitative IO score from five parameters: TMB · MSI · PD-L1 · driver penalty · ultra-low TMB penalty.
A sequence, not a single decision. Each line is annotated with ORR, PFS and OS evidence.
What to test at progression, which resistance mutations to expect, and which next-gen agents address each.
Professor of Medical Oncology at Acıbadem University, Istanbul. ASCO & ESMO member, author of 130+ peer-reviewed publications. Personally reviews and signs every advisory.
Clear packages. No hidden fees.
Two tiers based on how much support you need beyond the written report. Every case is signed by Prof. Yıldız.
Complete fourteen-section written interpretation, a definitive second read.
- 14-section structured IYGAS™ report
- Variant interpretation & therapy matching
- Active clinical trial recommendations
- 30-day email follow-up · 3-day delivery
Everything in Standard, plus a 30-minute video consultation with Prof. Yıldız.
- Everything in Standard
- 30-min video consult w/ Prof. Yıldız
- Priority turnaround in 48 hours
- 60-day follow-up · EN·TR·BG·RO·BA
Questions we hear most.
Your lab report is a technical document. It lists what was found but doesn’t build a strategy. We take that same data and produce a complete clinical roadmap: prioritization, IO assessment, resistance planning, trial matching.
We work with your existing report, no new testing required. We accept Tempus, FoundationOne CDx, Guardant360, Caris and others, and integrate multi-platform data (DNA + RNA + IHC).
No. Our report is a molecular advisory, a second opinion. All treatment decisions remain with your treating oncologist, who knows your full history. Physician review is required before any clinical action.
The structured IYGAS™ advisory is always in English, the international standard. The physician commentary is available in Turkish, English, Bulgarian, Romanian and Bosnian.
A molecular second opinion,
within days.
Upload your existing NGS report securely. Every case is personally reviewed and signed by Prof. İbrahim Yıldız.
Book a Consultation